

# IHC Evaluation of Select Protein Biomarkers in Metastatic NSCLC

Learn more at  
**DISCOVER MET**  
 A Pathology Resource



Staining Pattern	PD-L1 <sup>1-3</sup>	c-Met (MET) <sup>4-7</sup>	HER2 <sup>8-10†</sup>
<b>Cells Percentage Evaluated</b> % is expressed out of ≥100 viable TC.	Tumor cell percentage (TC%)* or tumor proportion score (TPS)	TC%	TC%
<b>Staining Intensities Observed</b>	Weak (1+), moderate (2+), and/or strong (3+)	Weak (1+), moderate (2+), and/or strong (3+)	Weak (1+), moderate (2+), and/or strong (3+)
<b>Cellular Component Evaluated</b>	Membrane only*	Membrane and/or cytoplasmic	Membrane only
<b>Membrane Staining</b>	Partial, basolateral, and/or circumferential/complete	Partial, basolateral, and/or circumferential/complete	Partial, basolateral, and/or circumferential/complete
<b>General IHC Assessment</b> TC% can be represented as discrete values, as a range, and/or as inequalities (ie, > or <).	<b>Percentage (%)*</b> <b>Negative:</b> Partial or complete staining in <1% of TC <b>Expression:</b> Partial or complete staining in 1–49% of TC <b>High Expression:</b> Partial or complete staining in ≥50% of TC	<b>Percentage (%) + Staining Intensity (+)</b> <b>Negative:</b> Absence (0) of detectable staining <b>Expression:†</b> TC% at 1+ staining TC% at 2+ staining TC% at 3+ staining	<b>Percentage (%) + Staining Intensity (+)</b> <b>Negative:</b> No staining or membranous reactivity in <10% of TC <b>IHC 1+:</b> Faint or barely perceptible staining in ≥10% of TC <b>IHC 2+:</b> Weak or moderate staining in ≥10% of TC <b>IHC 3+:</b> Strong staining in ≥10% of TC

This table may not be exhaustive of all evaluations of protein expression by IHC in metastatic NSCLC, which are subject to differences based on assay used and means of reporting. This table should not be considered as a replacement for assay-specific interpretation manuals or guides and is not an exhaustive list of NSCLC biomarkers.

\*Tumor-infiltrating immune cells and proportion of tumor area can also be a means of scoring PD-L1 in metastatic NSCLC when using appropriate associated assays. †Staining intensity can be represented as discrete values for a given TC%. ‡HER2 staining patterns for NSCLC are in alignment with the Gastric Cancer HER2 Protocol. The information provided pertains specifically to resection specimens.

HER2=human epidermal growth factor receptor 2; IHC=immunohistochemistry; NSCLC=non-small cell lung cancer; PD-L1=programmed death-ligand 1; TC=tumor cells.

**References:** 1. Yu H, et al. *J Thorac Oncol*. 2016;11(7):964-975. 2. PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC. 29158. 2021-04-06. 3. VENTANA PD-L1 (SP142) Assay Interpretation Guide for Urothelial Carcinoma. 1014987US Rev F. 2020-07-15. 4. Yin W, et al. *Cancers (Basel)*. 2022;14(10):2433. 5. VENTANA MET (SP44) RxDx Assay Interpretation Guide for Non-Squamous Non-Small Cell Lung Cancer. 1018336US Rev A. 2025-05-14. 6. Hartmaier RJ, et al. *Cancer Discov*. 2023;13(1):98-113. 7. Xiang C, et al. *Mod Pathol*. 2024;37(4):100451. 8. Lashkarizadeh M, et al. *Clin Respir J*. 2023;17(2):90-95. 9. Kim EK, et al. *PLoS One*. 2017;12(2):e0171280. 10. VENTANA anti-HER2/neu (4B5) Assay Interpretation Guide for Breast and Gastric Carcinoma. 101105800 Rev B. 2011-10-11.

© 2026 AbbVie Inc. All rights reserved.

ABBV-US-02067-MC, v2.0  
 Approved: April 2026

abbvie